Next Article in Journal
Molecular Epidemiology, Seasonality and Phylogenetic Investigations of Anaplasma ovis in Small Ruminants from Diverse Agro-Climatic Regions of Punjab, Pakistan
Previous Article in Journal
Re-Evaluation of the Cross-Reactions of the Antibody against the Causative Agent for Paracoccidioidomycosis Ceti; Paracoccidioides ceti and the Related Fungal Species
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Microorganisms
Volume 11
Issue 10
10.3390/microorganisms11102429
microorganisms-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

The Molecular Identification and Antifungal Susceptibility of Clinical Isolates of Aspergillus Section Flavi from Three French Hospitals

by
Elie Djenontin
1,2,
Jean-Marc Costa
3,
Bita Mousavi
1,
Lin Do Ngoc Nguyen
4,
Jacques Guillot
5,
Laurence Delhaes
6,
Françoise Botterel
1,2 and
Eric Dannaoui
1,7,8,*
1
Dynamyc UPEC, EnvA, USC Anses, Faculté de Médecine de Créteil, 94010 Créteil, France
2
Service de Parasitologie-Mycologie, Hôpital Universitaire Mondor, AP-HP, 8 Rue du Général Sarrail, 94010 Créteil, France
3
Laboratoire CERBA, 11 Rue de l’Équerre, 95310 Saint-Ouen-l’Aumône, France
4
Family Hospital, 73 Nguyen Huu Tho, Hai Chau, Danang 55000, Vietnam
5
Unité pédagogique de Dermatologie, Parasitologie, Mycologie, Ecole Nationale Vétérinaire Agroalimentaire et de l’Alimentation Nantes Atlantique, Oniris, 44300 Nantes, France
6
Laboratoire de Parasitologie-Mycologie, CNR des Aspergilloses Chroniques—CHU de Bordeaux, INSERM U1045—Univ. Bordeaux, 33000 Bordeaux, France
7
Faculté de Médecine, Université Paris Cité, 75006 Paris, France
8
Unité de Parasitologie-Mycologie, Hôpital Necker Enfants Malades, AP-HP, 149 Rue de Sèvres, 75015 Paris, France
*
Author to whom correspondence should be addressed.
Microorganisms 2023, 11(10), 2429; https://doi.org/10.3390/microorganisms11102429
Submission received: 7 September 2023 / Revised: 20 September 2023 / Accepted: 22 September 2023 / Published: 28 September 2023
(This article belongs to the Section Medical Microbiology)
Browse Figure
Versions Notes

Abstract

:
(1) Background: Aspergillus flavus is a cosmopolitan mold with medical, veterinary, and agronomic concerns. Its morphological similarity to other cryptic species of the Flavi section requires molecular identification techniques that are not routinely performed. For clinical isolates of Aspergillus section Flavi, we present the molecular identification, susceptibility to six antifungal agents, and clinical context of source patients. (2) Methods: One hundred forty fungal clinical isolates were included in the study. These isolates, recovered over a 15-year period (2001–2015), were identified based on their morphological characteristics as belonging to section Flavi. After the subculture, sequencing of a part of the β-tubulin and calmodulin genes was performed, and resistance to azole antifungals was screened on agar plates containing itraconazole and voriconazole. Minimum inhibitory concentrations were determined for 120 isolates by the European Committee on Antimicrobial Susceptibility Testing (EUCAST) broth microdilution method. (3) Results: Partial β-tubulin and calmodulin sequences analysis showed that 138/140 isolates were A. flavus sensu stricto, 1 isolate was A. parasiticus/sojae, and 1 was A. nomiae. Many of the isolates came from samples collected in the context of respiratory tract colonization. Among probable or proven aspergillosis, respiratory infections were the most frequent, followed by ENT infections. Antifungal susceptibility testing was available for isolates (n = 120, all A. flavus ss) from one hospital. The MIC range (geometric mean MIC) in mg/L was 0.5–8 (0.77), 0.5–8 (1.03), 0.125–2 (0.25), 0.03–2 (0.22), 0.25–8 (1.91), and 0.03–0.125 (0.061) for voriconazole, isavuconazole, itraconazole, posaconazole, amphotericin B, and caspofungin, respectively. Two (1.67%) isolates showed resistance to isavuconazole according to current EUCAST breakpoints with MICs at 8 mg/L for isavuconazole and voriconazole. One of these two isolates was also resistant to itraconazole with MIC at 2 mg/L. (4) Conclusions: The present characterization of a large collection of Aspergillus belonging to the Flavi section confirmed that A. flavus ss is the predominant species. It is mainly implicated in respiratory and ENT infections. The emergence of resistance highlights the need to perform susceptibility tests on section Flavi isolates.

1. Introduction

A. flavus is the second most common pathogenic species of Aspergillus in humans [1]. Indeed, A. flavus can be responsible for invasive aspergillosis (IA), chronic aspergillosis, and other infections [2]. A. flavus is the first cause of primary cutaneous aspergillosis [3,4]. Auricular and ocular localizations are frequently reported as keratitis and chronic otomycosis [5,6,7,8,9,10,11]. A. flavus is also the first agent of skull base aspergillosis, whose typical form is malignant external otitis [12,13,14,15,16,17], and the principal risk factor is diabetes [18]. A. flavus could also be implicated in many other clinical forms such as pulmonary invasive aspergillosis [19,20,21,22], chronic rhinosinusitis [23], brain abscesses [24], myositis [25,26], arthritis [27], spondylodiscitis [28,29], endocarditis [30,31], mediastinitis [32], eumycetoma [33], and allergic [34] or hypersensitivity syndromes like hot tub pneumonitis [35].
A. flavus is also of great importance due to its ability to cause disease in animals and crops and to produce carcinogenic mycotoxins [36]. Another epidemiological characteristic of A. flavus is its higher prevalence in tropical countries [37,38,39].
Section Flavi includes 35 species divided into eight series [40,41]. All these species share morphological characteristics, and some are morphologically indistinguishable. Nevertheless, whole-genome sequencing data have recently shown the genetic and metabolic diversity among the Flavi section [42]. Only A. flavus ss, A. nomiae, A. minisclerotigenes, A. tamarii, and A. alliaceus have been reported as pathogenic in humans [6,43,44,45].
Nevertheless, the prevalence of the different cryptic species in clinical samples is largely unknown, as is their pathogenicity. None of the cryptic species in section Flavi are known to carry natural resistance to antifungal drugs [46]. However, A. flavus shows high amphotericin B MICs compared to A. fumigatus [47].
The emergence of acquired azole resistance observed in the last 20 years in the genus Aspergillus has been mainly reported in A. fumigatus [48] but also affects other Aspergillus species [49,50,51,52]. The azole resistance of A. flavus clinical isolates has been reported since 2012 [53,54,55,56].
In this study, we molecularly analyze 140 isolates belonging to the Flavi section and determine the susceptibility profile for a subset (n = 120) of the isolates.

2. Materials and Methods

2.1. Study Design, Patients and Isolates

A total of 140 clinical isolates of Aspergillus section Flavi recovered from 107 patients were analyzed. Isolates were mainly cultured from respiratory samples (n = 114) and ENT sphere (n = 19). Seven isolates were cultured from other sites: two artery biopsies, dialysis fluid, nail, arm biopsy, hallux biopsy, and endocardial biopsy (Table S1). All isolates were collected between 2001 and 2015 through routine clinical work from patients of three hospitals: Hôpital Henri Mondor (HMN), Hôpital Universitaire de Lile (LIL), and Hôpital Européen Georges Pompidou (HEGP). The number of isolates collected each year was homogeneous over time, with 72 isolates between 2001 and 2008 and 68 isolates between 2009 and 2015. These isolates were stored frozen. Patients’ identifiable information had already been anonymized. Since the study was conducted on isolates collected through routine clinical work and patients’ identifiable information had already been anonymized, no written or verbal informed consent was necessary for patients to participate in this study. We testify that we followed the ethical standards of the Helsinki Declaration of 1975, as revised in 2008. Patients include lung transplant patients with cystic fibrosis and other pathologies, patients with hematological malignancies, and patients with ENT diseases and other pathologies. Clinical data showed that most of the isolates (96 isolates) were considered colonizers; 41 isolates were considered implicated in infections, including invasive pulmonary aspergillosis (12 isolates), otitis (12 isolates), bronchopulmonary aspergillosis (6 isolates), sinusitis (1 isolate), aspergilloma (1 isolate), endovascular infection (2 isolates), endocarditis (1 isolate), nasal aspergillosis (1 isolate), hallux infection (1 isolate), arm infection (1 isolate), and one disseminated invasive aspergillosis (1 isolate). For five isolates, clinical data were not available.

2.2. Molecular Identification

DNA extraction: Molds were subcultured in Sabouraud medium for 7 days at 35 °C. Conidia were subjected to a mechanical shock with MagNA Lyser Green Beads (Roche Diagnostics, Meylan, France) in MagNA Lyser Instrument (Roche) and thermal shock in the ice to disrupt the wall. Then, after 4 h incubation at 56 °C with proteinase K (Qiagen Sciences Inc., Courtaboeuf, France), DNA was extracted using the QIAamp DNA Blood Mini Kit (Qiagen Sciences Inc.) following the manufacturer’s instructions.
Sequencing: Molecular identification was performed by partial sequencing of the β-tubulin and calmodulin genes using primers bt2a (5′-GGTAACCAAATCGGTGCTGCTTTC-3′); bt2b (5′-ACCCTCAGTGTAGTGACCCTTGGC-3′) designed by Glass and Donaldson [57] and cmd5 (5′-CCGAGTACAAGGARGCCTTC-3′); cmd6 (5′-CCGATRGAGGTCATRACGTGG-3′) designed by Hong et al. [58]. Primers were synthesized by Sigma-Aldrich (Saint Quentin-Fallavier, France). Each sample reaction mixture contained 4 µM (1 µL at 100 µM) of each primer; 2 mM MgCl2 included in 2.5 µL of 10X PCR buffer (FastSart Taq DNA Polymerase Kit, Roche); 200 µM of (0.5 µL at 10 mM) dNTP solution (EMD Millipore Corp, Burlington, MA, USA); 0.04 U (0.2 µL at 5 U/µL) of FastStart Taq DNA Polymerase (FastSart Taq DNA Polymerase Kit, Roche); 5 µL (20 ng) of genomic DNA (DNA extracts were diluted to standardize the DNA concentration at 4 ng/μL); and DNase-free water, up to a final reaction volume of 25 µL.
Amplification was performed on a Gene Amp® PCR System 9700 (Applied Biosystems; Thermo Fisher, Waltham, MA, USA). The PCR conditions were initial denaturation at 95 °C for 10 min, followed by 35 cycles of denaturation at 95 °C for 30 s, annealing at 55 °C for 30 s, extension at 72 °C for 1 min, and final extension at 72 °C for 10 min.
After purification through columns of the MinElute PCR Purification Kit (Qiagen Sciences Ing.), sequencing was performed by Sanger’s method (IMRB Genomics Platform). Sequences were analyzed using Bioedit (Hall, T.A. Version 7.2.5). Each sequence from our isolates was compared to the sequence of the type strains of each species within the Flavi section. Sequences used for comparison are based on the most recent taxonomic revision of the Flavi section published by Houbraken et al. in 2020 [41]. These sequences are presented in Table S2. Isolates were identified to a given species if the homologies with sequences of type strains were >98%. When there were mismatches between calmodulin and beta-tubulin, we used the most discriminating gene (between beta-tubulin and calmodulin) as defined by Houbraken et al. [41]. Phylogenetic trees of β-tubulin and calmodulin genes were built with maximum parsimony likelihood method with MEGA (Version 11.0.13) software. β-tubulin and calmodulin genes partial sequences were concatenated, and phylogenetic trees were also generated with these concatenated sequences. Using a heatmap, we labeled the tree obtained from the concatenation of calmodulin and β-tubulin with the MICs for each isolate.

2.3. Antifungal Susceptibility Testing

Isolates were revived from storage and subcultured on Sabouraud-agar slanted tubes. In vitro resistance to azoles was screened by subculturing each isolate on RPMI agar plates supplemented with itraconazole (Sigma-Aldrich, Saint-Quentin Fallavier, France) at 4 mg/L and voriconazole (Sigma-Aldrich) at 1 mg/L, as previously described [59]. After that, MICs for azoles were determined by EUCAST method.
The antifungal agents used in this study were amphotericin B (Sigma-Aldrich, Saint Quentin-Fallavier, France), itraconazole (Sigma-Aldrich), voriconazole (Pfizer Inc., New-York, NY, USA), isavuconazole (Basilea, Bâle, Suisse), posaconazole (Merck & Co Inc., Kenilworth, NJ, USA), and caspofungin (Merck & Co Inc.). The final concentrations tested ranged from 0.015 to 8 mg/L for each drug. Plates were incubated at 35 °C for 48 h in a humidified atmosphere. After incubation, the microplates were read with a reading mirror (for all drugs but caspofungin) to visualize the fungal growth in each well and determine the MIC as the lowest concentration with no visible growth. For caspofungin, an inverted microscope was used to determine the antifungal concentration that produced a visible change in the morphology of the hyphae compared with the growth control well (Minimum Effective Concentration). The EUCAST has set breakpoints for the interpretation of antifungal susceptibility testing results for itraconazole (Resistant isolates: MIC > 1 mg/L) and isavuconazole (Resistant isolates: MIC > 2 mg/L) [60]. For other antifungal drugs, breakpoints are not available, and we used ECOFFs for the interpretation: isolates were considered non-wild type when MIC was >4 mg/L for amphotericin B; >2 mg/L for voriconazole and >0.5 mg/L for posaconazole. Breakpoints and ECOFFs of echinocandins have not been set yet, and rates of resistance have not been calculated. A. flavus ATCC 204304, Candida krusei ATCC 6258, and Candida parapsilosis ATCC 22019 were used as quality control strains.

3. Results

3.1. Molecular Identification and Cryptic Species

Sequence analysis showed that 138 isolates were A. flavus ss, and two isolates were different cryptic species, A. parasisticus/sojae and A. nomiae. A. flavus ss sequences have been deposited in GenBank with accession numbers from OR285555 to OR285692 for beta-tubulin and accession numbers from OR226374 to OR266455 and from OR285498 to OR2885554 for calmodulin. For β-tubulin sequences, the phylogenetic trees built with 458 bp alignment length are shown in Figure S2. For calmodulin sequences, the phylogenetic trees built with 512 bp alignment length are shown in Figure S3. Among A. flavus ss isolates, 5 and 10 different sequence patterns were identified for β-tubulin and calmodulin, respectively (Tables S3 and S4).
The β-tubulin sequence (GenBank accession number OR455454) of isolate HEGP 1350 showed 99.7% and 97% homology with the reference sequences of A. nomiae and A. pseudonomiae, respectively. The calmodulin sequence (GenBank accession number OR455456) of isolate HEGP 1350 showed 98.6% and 99.1% homology with A. nomiae and pseudonomiae reference sequences, respectively. We conclude that this isolate is A. nomiae.
The β-tubulin sequence (GenBank access number OR455455) of isolate HEGP 3223 showed 99.2% and 100% homology with the reference sequences of A. parasiticus and A. sojae, respectively. The calmodulin sequence (GenBank access number OR455457) of isolate HEGP 3223 showed 100% homology with the reference sequences of A. parasiticus and A. sojae, respectively.
The phylogenetic tree of concatenated calmodulin and β-tubulin sequences is presented in Figure 1. Concatenated calmodulin and β-tubulin sequences showed 15 patterns (Table S5).

3.2. Antifungal Susceptibility Testing and Azole MICs Distribution

For logistical reasons, we were only able to determine MICs on 120 isolates from the HEGP hospital. Resistance screening revealed two voriconazole-resistant isolates collected in December 2005 and September 2007 among the 120 A. flavus ss isolates.
Table 1 and Table 2 show the distribution and values of MICs for the 120 A. flavus ss determined by the EUCAST method. For A. flavus ss isolates, the geometric mean MICs of voriconazole, isavuconazole, itraconazole, posaconazole, amphotericin B, and caspofungin were 0.78, 1.04, 0.25, 0.22, 1.90, and 0.06 mg/L, respectively. Of the 120 A. flavus ss isolates, 2 (1.67%) had isavuconazole MICs higher than clinical breakpoints. These two isolates were cross-resistant to voriconazole and isavuconazole with MICs of 8 mg/L for both drugs and were non-wild type for posaconazole with MICs of 1 mg/L. One of these two isolates had an itraconazole MIC of 2 mg/L, which can be interpreted as resistance to this drug. Of the remaining isolates, six others had posaconazole MICs of 1 mg/L, and one isolate had an amphotericin MIC of 8 mg/L. Table 3 shows MICs for A. nomiae and A. parasiticus/sojae. Geometric mean MICs were 0.50, 0.71, 0.35, 0.18, 2.83, and 0.04 mg/L for voriconazole, isavuconazole, itraconazole, posaconazole, amphotericin B, and caspofungin, respectively.

4. Discussion

In the present study, we report on the precise identification of a large collection of Flavi section isolates and their antifungal susceptibility. Given their importance in human, animal, and plant pathologies and their use in food and pharmaceutical industries, a better knowledge of the species of section Flavi is of prime importance. According to the last taxonomical revision, the Flavi section comprises 35 species grouped in eight series [41]. In the present study, most of the isolates were A. flavus ss (98.4%), showing that cryptic species seem to be rare in clinical samples. Within A. flavus ss isolates, calmodulin polymorphism was more marked than beta-tubulin polymorphism, as also observed by Frisvad [40]. The former led to the definition of 10 clusters, while the latter revealed 5 clusters. Concatenation of the two sequences revealed 15 clusters. Overlaying these clusters with susceptibility data revealed no specific profile for any given cluster. Based on calmodulin and beta-tubulin partial sequences, only two cryptic species were identified: A. parasiticus/sojae and A. nomiae. As the epidemiology of Aspergillus may depend on climatic conditions and the type of patients hospitalized, our results do not necessarily reflect the overall epidemiology in hospitals in France. Despite the mismatch between calmodulin and beta-tubulin for isolate HEGP 1350, since beta-tubulin is discriminating between A. nomiae and A. pseudonomiae, whereas calmodulin is not [40], we concluded that our isolate is A. nomiae. Neither beta-tubulin nor calmodulin discriminate between A. parasiticus and A. sojae. A. sojae is a domesticated nontoxigenic species associated with A. parasiticus, as A. oryzae is associated with A. flavus [40,65]. Several cases of infection due to cryptic species of section Flavi have been reported in the literature (Table 4). Some cases of A. flavus ss infection reported in France, with underlying disease, treatment, and outcome, are presented in Table S5. A. parasiticus and A. nomiae are two of the major aflatoxin-producing species. A. nomiae has been reported in cases of pulmonary disease [46,66,67,68], onychomycosis [69], keratitis [6,70], and rhinofacial aspergillosis [71]. In our study, both species were recovered from pulmonary specimens but were considered colonizers. Among the other cryptic species, A. pseudonomiae has been reported in a sinus tissue sample from a patient with fungal rhinosinusitis [72] and in keratitis [73]. A. alliaceus, A. caelatus, A. minisclerotigenes, A. novoparasiticus, A. tamarii, A. pseudotamarii, and A. oryzae var. effusus are the other cryptic species that have been isolated from clinical samples. A. tamarii has been reported as a cause of primary cutaneous aspergillosis [74,75], wound infection [72,76,77], onychomycosis [78], keratitis [6,7,8,9,10,79], and invasive nasosinusal aspergillosis [80,81]. A. pseudotamarii could also cause keratitis [11]. A. alliaceus is an etiological agent of invasive pulmonary aspergillosis [46,82,83], and this species produces ochratoxin [84]. A. oryzae var. effusus has been reported as a cause of keratitis [6] and has been isolated from the lower respiratory tract of hospitalized patients [85]. In 2019, one case of A. caelatus airway colonization in a chronic obstructive pulmonary disease patient was reported in Colombia [86]. A. minisclerotigenes has been reported as a cause of sinus [45] infection and keratitis [87]. A. novoparasiticus has been isolated from the sputum of a patient in São Paulo, Brazil [88]. The low number of clinical cases could be explained by an underestimation of cryptic species due to their difficulty in identification. Although molecular sequencing of β-tubulin/calmodulin remains the gold standard for a precise species identification, new technologies such as whole-genome sequencing are now used for taxonomic purposes [89]. Other molecular techniques are also available for assessing the genetic diversity among A. flavus isolates [90]. Mass spectrometry may be interesting in routine clinical microbiology laboratories [91]. Environment plays an important role in the epidemiology of A. flavus human infection. Infections due to this species are more prevalent in dry and hot climatic regions, and some clinical cases reported in France are imported infections contracted in Africa [24,25,32]. Infections are mostly acquired by exposure to A. flavus spores in the environment, and nosocomial infections in hospitals have also been reported from surgery unit air and surface [30,92].
Among our isolates, two resistant isolates (1.67%) with voriconazole and isavuconazole MICs of 8 mg/L recovered from patients with long-term treatment with voriconazole were detected. This observation is in favor of the selection for cross-resistance to voriconazole and isavuconazole by antifungal pressure during the patient’s treatment with voriconazole. The first clinical isolate of voriconazole-resistant A. flavus has been recovered from the lung biopsy of a Chinese patient who had also previously been treated with voriconazole [53]. Voriconazole-resistant isolates have been reported from China [53], India [54,55,93], South Korea [56], and Spain [94,95], with a prevalence between 2.5 and 14% among clinical isolates. One of our isolates showed amphotericin MIC at 8 mg/L. Cases of resistance to amphotericin B have also been reported, and the MICs of amphotericin B for A. flavus are generally higher than for A. fumigatus [96]. In the present study, none of the azole-resistant isolates and isolates with MICs of 8 mg/L for amphotericin B were involved in invasive aspergillosis.
The emergence of resistant isolates highlights the importance of antifungal susceptibility testing, particularly for patients undergoing long-term treatment. The best techniques are the microdilution broth reference techniques (EUCAST or CLSI), but other techniques, such as the concentration gradient strip (CGS) method, can also be used. Indeed, it has been shown that the results obtained with the CGS method correlated well with those obtained with the reference techniques for A. flavus [97].

5. Conclusions

This study demonstrated that cryptic species within the Flavi section and azole-resistant A. flavus ss can be found among clinical isolates. Therefore, precise identification to the species level and routine antifungal susceptibility testing are needed.

Supplementary Materials

The following supporting information can be downloaded at https://www.mdpi.com/article/10.3390/microorganisms11102429/s1. Table S1: List of isolates with origin of samples, diagnosis, clinical context; Table S2: Reference strains list; Table S3: Variability of β-tubulin sequences (β-tubulin and calmodulin); Table S4: Variability of calmodulin sequences; Table S5: Sequence types after concatenation of calmodulin and β-tubulin; Table S6: Cases of A. flavus ss infection reported in France; Figure S1: Origin of samples; Figure S2: Phylogenetic tree of A. flavus partial β-tubulin sequences; Figure S3: Phylogenetic tree of A. flavus partial calmodulin sequences.

Author Contributions

Conceptualization, F.B. and E.D. (Eric Dannaoui); methodology, E.D. (Elie Djenontin), J.-M.C., L.D.N.N. and B.M.; formal analysis, E.D. (Elie Djenontin), F.B. and E.D. (Eric Dannaoui); writing—original draft preparation, E.D. (Elie Djenontin) and E.D. (Eric Dannaoui); writing—review and editing, E.D. (Elie Djenontin), B.M., L.D.N.N., J.G., L.D., F.B. and E.D. (Eric Dannaoui). All authors have read and agreed to the published version of the manuscript.

Funding

This research received no external funding.

Data Availability Statement

All MIC data are presented within the manuscript.

Conflicts of Interest

Over the past 5 years, Eric Dannaoui has received research grants from MSD and Gilead; travel grants from Gilead, MSD, Pfizer, and Astellas; and speaker’s fees from Gilead, MSD, and Astellas. The other authors declare no conflict of interest.

References

  1. Hedayati, M.T.; Pasqualotto, A.C.; Warn, P.A.; Bowyer, P.; Denning, D.W. Aspergillus flavus: Human Pathogen, Allergen and Mycotoxin Producer. Microbiology 2007, 153, 1677–1692. [Google Scholar] [CrossRef] [PubMed]
  2. Rudramurthy, S.M.; Paul, R.A.; Chakrabarti, A.; Mouton, J.W.; Meis, J.F. Invasive Aspergillosis by Aspergillus flavus: Epidemiology, Diagnosis, Antifungal Resistance, and Management. J. Fungi 2019, 5, 55. [Google Scholar] [CrossRef] [PubMed]
  3. Bernardeschi, C.; Foulet, F.; Ingen-Housz-Oro, S.; Ortonne, N.; Sitbon, K.; Quereux, G.; Lortholary, O.; Chosidow, O.; Bretagne, S. Cutaneous Invasive Aspergillosis: Retrospective Multicenter Study of the French Invasive-Aspergillosis Registry and Literature Review. Medicine 2015, 94, e1018. [Google Scholar] [CrossRef] [PubMed]
  4. Chakrabarti, A.; Gupta, V.; Biswas, G.; Kumar, B.; Sakhuja, V.K. Primary Cutaneous Aspergillosis: Our Experience in 10 Years. J. Infect. 1998, 37, 24–27. [Google Scholar] [CrossRef] [PubMed]
  5. Adoubryn, K.D.; N’Gattia, V.K.; Kouadio-Yapo, G.C.; Nigué, L.; Zika, D.K.; Ouhon, J. Epidemiology of otomycoses at the University Hospital of Yopougon (Abidjan-Ivory Coast). J. Mycol. Med. 2014, 24, e9–e15. [Google Scholar] [CrossRef]
  6. Al-Hatmi, A.M.S.; Castro, M.A.; de Hoog, G.S.; Badali, H.; Alvarado, V.F.; Verweij, P.E.; Meis, J.F.; Zago, V.V. Epidemiology of Aspergillus Species Causing Keratitis in Mexico. Mycoses 2019, 62, 144–151. [Google Scholar] [CrossRef]
  7. Manikandan, P.; Varga, J.; Kocsubé, S.; Anita, R.; Revathi, R.; Németh, T.M.; Narendran, V.; Vágvölgyi, C.; Panneer Selvam, K.; Shobana, C.S.; et al. Epidemiology of Aspergillus Keratitis at a Tertiary Care Eye Hospital in South India and Antifungal Susceptibilities of the Causative Agents. Mycoses 2013, 56, 26–33. [Google Scholar] [CrossRef]
  8. Cuadros, J.; Gros-Otero, J.; Gallego-Angui, P.; Scheu, A.K.; Montes-Mollon, A.; Pérez-Rico, C.; Moreno, J.P.; Gomez-Herruz, P.; Soliveri, J.; Teus, M. Aspergillus tamarii Keratitis in a Contact Lens Wearer. Med. Mycol. Case Rep. 2017, 11, 21–24. [Google Scholar] [CrossRef]
  9. Kredics, L.; Varga, J.; Kocsubé, S.; Doczi, I.; Samson, R.A.; Rajaraman, R.; Narendran, V.; Bhaskar, M.; Vagvolgyi, C.; Manikandan, P. Case of Keratitis Caused by Aspergillus tamarii. J. Clin. Microbiol. 2007, 45, 3464–3467. [Google Scholar] [CrossRef]
  10. Homa, M.; Manikandan, P.; Szekeres, A.; Kiss, N.; Kocsubé, S.; Kredics, L.; Papp, T. Characterization of Aspergillus tamarii Strains from Human Keratomycoses: Molecular Identification, Antifungal Susceptibility Patterns and Cyclopiazonic Acid Producing Abilities. Front. Microbiol. 2019, 10, 2249. [Google Scholar] [CrossRef]
  11. Baranyi, N.; Kocsubé, S.; Szekeres, A.; Raghavan, A.; Narendran, V.; Vágvölgyi, C.; Panneer Selvam, K.; Babu Singh, Y.R.; Kredics, L.; Varga, J.; et al. Keratitis Caused by Aspergillus pseudotamarii. Med. Mycol. Case Rep. 2013, 2, 91–94. [Google Scholar] [CrossRef] [PubMed]
  12. Pichon, M.; Joly, V.; Argy, N.; Houze, S.; Bretagne, S.; Alanio, A.; Wassef, M.; Verillaud, B.; Yazdanpanah, Y. Aspergillus flavus Malignant External Otitis in a Diabetic Patient: Case Report and Literature Review. Infection 2020, 48, 193–203. [Google Scholar] [CrossRef] [PubMed]
  13. Morgand, M.; Rammaert, B.; Poirée, S.; Bougnoux, M.-E.; Tran, H.; Kania, R.; Chrétien, F.; Jouvion, G.; Lortholary, O. Chronic Invasive Aspergillus Sinusitis and Otitis with Meningeal Extension Successfully Treated with Voriconazole. Antimicrob. Agents Chemother. 2015, 59, 7857–7861. [Google Scholar] [CrossRef] [PubMed]
  14. Marchionni, E.; Parize, P.; Lefevre, A.; Vironneau, P.; Bougnoux, M.E.; Poiree, S.; Coignard-Biehler, H.; DeWolf, S.E.; Amazzough, K.; Barchiesi, F.; et al. Aspergillus spp. Invasive External Otitis: Favourable Outcome with a Medical Approach. Clin. Microbiol. Infect. 2016, 22, 434–437. [Google Scholar] [CrossRef] [PubMed]
  15. Moniot, M.; Montava, M.; Ranque, S.; Scemama, U.; Cassagne, C.; Arthur, V. Malignant Aspergillus flavus Otitis Externa with Jugular Thrombosis. Emerg. Infect. Dis. 2019, 25, 830–832. [Google Scholar] [CrossRef]
  16. Noroy, L.; Pujo, K.; Leghzali-Moise, H.; Saison, J. Aspergillus Necrotizing Otitis Externa with Temporomandibulozygomatic Involvement. Eur. Ann. Otorhinolaryngol. Head. Neck Dis. 2020, 137, 127–129. [Google Scholar] [CrossRef]
  17. Clerc, N.L.; Verillaud, B.; Duet, M.; Guichard, J.-P.; Herman, P.; Kania, R. Skull Base Osteomyelitis: Incidence of Resistance, Morbidity, and Treatment Strategy. Laryngoscope 2014, 124, 2013–2016. [Google Scholar] [CrossRef]
  18. Gabrielli, E.; Fothergill, A.W.; Brescini, L.; Sutton, D.A.; Marchionni, E.; Orsetti, E.; Staffolani, S.; Castelli, P.; Gesuita, R.; Barchiesi, F. Osteomyelitis Caused by Aspergillus Species: A Review of 310 Reported Cases. Clin. Microbiol. Infect. 2014, 20, 559–565. [Google Scholar] [CrossRef]
  19. Langlois, M.-E.; Lorillou, M.; Ferry, T.; Chidiac, C.; Valour, F. Cystic Lung Lesions Revealing a Pneumocystis jirovecii and Aspergillus flavus Co-Infection in an HIV-Infected Patient. Int. J. Infect. Dis. 2015, 37, 143–144. [Google Scholar] [CrossRef]
  20. Caillet, A.; Bellanger, A.-P.; Navellou, J.C.; Daguindau, E.; Rocchi, S.; Scherer, E.; Berceanu, A.; Millon, L. Refractory Invasive Pulmonary Aspergillosis Due to Aspergillus flavus Detected with the Combination of Two in-House Aspergillus qPCR. J. Mycol. Med. 2023, 33, 101350. [Google Scholar] [CrossRef]
  21. Florent, M.; Katsahian, S.; Vekhoff, A.; Levy, V.; Rio, B.; Marie, J.-P.; Bouvet, A.; Cornet, M. Prospective Evaluation of a Polymerase Chain Reaction–ELISA Targeted to Aspergillus fumigatus and Aspergillus flavus for the Early Diagnosis of Invasive Aspergillosis in Patients with Hematological Malignancies. J. Infect. Dis. 2006, 193, 741–747. [Google Scholar] [CrossRef] [PubMed]
  22. Lortholary, O.; Gangneux, J.-P.; Sitbon, K.; Lebeau, B.; de Monbrison, F.; Le Strat, Y.; Coignard, B.; Dromer, F.; Bretagne, S. French Mycosis Study Group Epidemiological Trends in Invasive Aspergillosis in France: The SAIF Network (2005–2007). Clin. Microbiol. Infect. 2011, 17, 1882–1889. [Google Scholar] [CrossRef] [PubMed]
  23. Comacle, P.; Belaz, S.; Jegoux, F.; Ruaux, C.; Le Gall, F.; Gangneux, J.-P.; Robert-Gangneux, F. Contribution of Molecular Tools for the Diagnosis and Epidemiology of Fungal Chronic Rhinosinusitis. Med. Mycol. 2016, 54, 794–800. [Google Scholar] [CrossRef] [PubMed]
  24. Brun, S.; Fekkar, A.; Busse, A.; Seilhean, D.; Lecsö, M.; Adler, D.; Prodanovic, H.; Mazier, D.; Datry, A. Aspergillus flavus Brain Abscesses Associated with Hepatic Amebiasis in a Non-Neutropenic Man in Senegal. Am. J. Trop. Med. Hyg. 2009, 81, 583–586. [Google Scholar] [CrossRef] [PubMed]
  25. Zaidan, M.; Ottaviani, S.; Polivka, M.; Bouldouyre, M.-A.; Orcel, P.; Richette, P. Aspergillus-Related Myositis: A Case Report and Review of the Literature. Semin. Arthritis Rheum. 2011, 41, 230–235. [Google Scholar] [CrossRef] [PubMed]
  26. Li, D.M.; Xiu, D.R.; Li, R.Y.; Samson, R.A.; de Hoog, G.S.; Wang, D.L. Aspergillus flavus Myositis in a Patient after Liver Transplantation. Clin. Transplant. 2008, 22, 508–511. [Google Scholar] [CrossRef]
  27. Gamaletsou, M.N.; Rammaert, B.; Bueno, M.A.; Sipsas, N.V.; Moriyama, B.; Kontoyiannis, D.P.; Roilides, E.; Zeller, V.; Taj-Aldeen, S.J.; Henry, M.; et al. Aspergillus Arthritis: Analysis of Clinical Manifestations, Diagnosis, and Treatment of 31 Reported Cases. Med. Mycol. 2017, 55, 246–254. [Google Scholar] [CrossRef]
  28. Cortet, B.; Richard, R.; Deprez, X.; Lucet, L.; Flipo, R.M.; Le Loët, X.; Duquesnoy, B.; Delcambre, B. Aspergillus Spondylodiscitis: Successful Conservative Treatment in 9 Cases. J. Rheumatol. 1994, 21, 1287–1291. [Google Scholar]
  29. Nicolle, A.; de la Blanchardière, A.; Bonhomme, J.; Hamon, M.; Leclercq, R.; Hitier, M. Aspergillus Vertebral Osteomyelitis in Immunocompetent Subjects: Case Report and Review of the Literature. Infection 2013, 41, 833–840. [Google Scholar] [CrossRef]
  30. Dupouey, J.; Faucher, B.; Normand, A.-C.; Hadrich, I.; Ranque, S.; Dumon, H.; Casalta, J.-P.; Collart, F.; Piarroux, R. Late Post-Operative Aspergillus flavus Endocarditis: Demonstration of a Six Years Incubation Period Using Microsatellite Typing. Med. Mycol. Case Rep. 2012, 1, 29–31. [Google Scholar] [CrossRef]
  31. Demaria, R.G.; Dürrleman, N.; Rispail, P.; Margueritte, G.; Macia, J.C.; Aymard, T.; Frapier, J.M.; Albat, B.; Chaptal, P.A. Aspergillus flavus Mitral Valve Endocarditis after Lung Abscess. J. Heart Valve Dis. 2000, 9, 786–790. [Google Scholar] [PubMed]
  32. Stern, J.-B.; Wyplosz, B.; Validire, P.; Angoulvant, A.; Fregeville, A.; Caliandro, R.; Gossot, D. Bulky Mediastinal Aspergillosis Mimicking Cancer in an Immunocompetent Patient. Ann. Thorac. Surg. 2014, 98, 1472–1475. [Google Scholar] [CrossRef] [PubMed]
  33. Ahmed, S.A.; Abbas, M.A.; Jouvion, G.; Al-Hatmi, A.M.S.; de Hoog, G.S.; Kolecka, A.; Mahgoub, E.S. Seventeen Years of Subcutaneous Infection by Aspergillus flavus; Eumycetoma Confirmed by Immunohistochemistry. Mycoses 2015, 58, 728–734. [Google Scholar] [CrossRef] [PubMed]
  34. Serrano, E.; Percodani, J.; Uro-Coste, E.; Yardeni, E.; Abbal, M.; Linas, M.D.; Recco, P.; Delisle, M.B. Value of Investigation in the Diagnosis of Allergic Fungal Rhinosinusitis: Results of a Prospective Study. J. Laryngol. Otol. 2001, 115, 184–189. [Google Scholar] [CrossRef]
  35. Saussereau, J.; Reboux, G.; Sfeir, G.; Dalphin, J.-C. Two cases of hot tub lung disease: Environmental investigations. Rev. Mal. Respir. 2019, 36, 204–208. [Google Scholar] [CrossRef]
  36. Varga, J.; Frisvad, J.C.; Samson, R.A. Two New Aflatoxin Producing Species, and an Overview of Aspergillus Section Flavi. Stud. Mycol. 2011, 69, 57–80. [Google Scholar] [CrossRef] [PubMed]
  37. Khairallah, S.H.; Byrne, K.A.; Tabbara, K.F. Fungal Keratitis in Saudi Arabia. Doc. Ophthalmol. 1992, 79, 269–276. [Google Scholar] [CrossRef]
  38. Kameswaran, M.; al-Wadei, A.; Khurana, P.; Okafor, B.C. Rhinocerebral Aspergillosis. J. Laryngol. Otol. 1992, 106, 981–985. [Google Scholar] [CrossRef]
  39. Mahgoub, E.S.; El Hassan, A.M. Pulmonary Aspergillosis Caused by Aspergillus flavus. Thorax 1972, 27, 33–37. [Google Scholar] [CrossRef]
  40. Frisvad, J.C.; Hubka, V.; Ezekiel, C.N.; Hong, S.-B.; Nováková, A.; Chen, A.J.; Arzanlou, M.; Larsen, T.O.; Sklenář, F.; Mahakarnchanakul, W.; et al. Taxonomy of Aspergillus Section Flavi and Their Production of Aflatoxins, Ochratoxins and Other Mycotoxins. Stud. Mycol. 2019, 93, 1–63. [Google Scholar] [CrossRef]
  41. Houbraken, J.; Kocsubé, S.; Visagie, C.M.; Yilmaz, N.; Wang, X.-C.; Meijer, M.; Kraak, B.; Hubka, V.; Bensch, K.; Samson, R.A.; et al. Classification of Aspergillus, Penicillium, Talaromyces and Related Genera (Eurotiales): An Overview of Families, Genera, Subgenera, Sections, Series and Species. Stud. Mycol. 2020, 95, 5–169. [Google Scholar] [CrossRef] [PubMed]
  42. Kjærbølling, I.; Vesth, T.; Frisvad, J.C.; Nybo, J.L.; Theobald, S.; Kildgaard, S.; Petersen, T.I.; Kuo, A.; Sato, A.; Lyhne, E.K.; et al. A Comparative Genomics Study of 23 Aspergillus Species from Section Flavi. Nat. Commun. 2020, 11, 1106. [Google Scholar] [CrossRef] [PubMed]
  43. Krishnan, S.; Manavathu, E.K.; Chandrasekar, P.H. Aspergillus flavus: An Emerging Non-fumigatus Aspergillus Species of Significance. Mycoses 2009, 52, 206–222. [Google Scholar] [CrossRef] [PubMed]
  44. Al-Wathiqi, F.; Ahmad, S.; Khan, Z. Molecular Identification and Antifungal Susceptibility Profile of Aspergillus flavus Isolates Recovered from Clinical Specimens in Kuwait. BMC Infect. Dis. 2013, 13, 126. [Google Scholar] [CrossRef]
  45. Dehghan, P.; Bui, T.; Campbell, L.T.; Lai, Y.-W.; Tran-Dinh, N.; Zaini, F.; Carter, D.A. Multilocus Variable-Number Tandem-Repeat Analysis of Clinical Isolates of Aspergillus flavus from Iran Reveals the First Cases of Aspergillus minisclerotigenes Associated with Human Infection. BMC Infect. Dis. 2014, 14, 358. [Google Scholar] [CrossRef]
  46. Fernandez-Pittol, M.; Alejo-Cancho, I.; Rubio-García, E.; Cardozo, C.; Puerta-Alcalde, P.; Moreno-García, E.; Garcia-Pouton, N.; Garrido, M.; Villanueva, M.; Alastruey-Izquierdo, A.; et al. Aspergillosis by Cryptic Aspergillus Species: A Case Series and Review of the Literature. Rev. Iberoam. Micol. 2022, 39, 44–49. [Google Scholar] [CrossRef] [PubMed]
  47. Dannaoui, E.; Persat, F.; Monier, M.F.; Borel, E.; Piens, M.A.; Picot, S. In-Vitro Susceptibility of Aspergillus spp. Isolates to Amphotericin B and Itraconazole. J. Antimicrob. Chemother. 1999, 44, 553–555. [Google Scholar] [CrossRef]
  48. Meis, J.F.; Chowdhary, A.; Rhodes, J.L.; Fisher, M.C.; Verweij, P.E. Clinical Implications of Globally Emerging Azole Resistance in Aspergillus fumigatus. Philos. Trans. R. Soc. Lond. B Biol. Sci. 2016, 371, 460. [Google Scholar] [CrossRef]
  49. Imbert, S.; Normand, A.C.; Ranque, S.; Costa, J.M.; Guitard, J.; Accoceberry, I.; Bonnal, C.; Fekkar, A.; Bourgeois, N.; Houzé, S.; et al. Species Identification and in Vitro Antifungal Susceptibility of Aspergillus terreus Species Complex Clinical Isolates from a French Multicenter Study. Antimicrob. Agents Chemother. 2018, 62, e02315-17. [Google Scholar] [CrossRef]
  50. Simon, L.; Déméautis, T.; Dupont, D.; Kramer, R.; Garnier, H.; Durieu, I.; Sénéchal, A.; Reix, P.; Couraud, S.; Devouassoux, G.; et al. Azole Resistance in Aspergillus fumigatus Isolates from Respiratory Specimens in Lyon University Hospitals, France: Prevalence and Mechanisms Involved. Int. J. Antimicrob. Agents 2021, 58, 106447. [Google Scholar] [CrossRef]
  51. Monpierre, L.; Desbois-Nogard, N.; Valsecchi, I.; Bajal, M.; Angebault, C.; Miossec, C.; Botterel, F.; Dannaoui, É. Azole Resistance in Clinical and Environmental Aspergillus Isolates from the French West Indies (Martinique). J. Fungi 2021, 7, 355. [Google Scholar] [CrossRef] [PubMed]
  52. Hamprecht, A.; Morio, F.; Bader, O.; Le Pape, P.; Steinmann, J.; Dannaoui, E. Azole Resistance in Aspergillus fumigatus in Patients with Cystic Fibrosis: A Matter of Concern? Mycopathologia 2018, 183, 151–160. [Google Scholar] [CrossRef] [PubMed]
  53. Liu, W.; Sun, Y.; Chen, W.; Liu, W.; Wan, Z.; Bu, D.; Li, R. The T788G Mutation in the cyp51C Gene Confers Voriconazole Resistance in Aspergillus flavus Causing Aspergillosis. Antimicrob. Agents Chemother. 2012, 56, 2598–2603. [Google Scholar] [CrossRef] [PubMed]
  54. Paul, R.A.; Rudramurthy, S.M.; Meis, J.F.; Mouton, J.W.; Chakrabarti, A. A Novel Y319H Substitution in CYP51C Associated with Azole Resistance in Aspergillus flavus. Antimicrob. Agents Chemother. 2015, 59, 6615–6619. [Google Scholar] [CrossRef] [PubMed]
  55. Paul, R.A.; Rudramurthy, S.M. Magnitude of Voriconazole Resistance in Clinical and Environmental Isolates of Aspergillus flavus and Investigation into the Role of Multidrug Efflux. Antimicrob. Agents Chemother. 2018, 62, e01022-18. [Google Scholar] [CrossRef]
  56. Choi, M.J.; Won, E.J.; Joo, M.Y.; Park, Y.-J.; Kim, S.H.; Shin, M.G.; Shin, J.H. Emergence of Voriconazole-Resistant Aspergillus flavus Isolates in Korean Hospitals: Microsatellite Typing and Resistance Mechanism Analysis. Antimicrob. Agents Chemother. 2019, 63, e01610–e01618. [Google Scholar] [CrossRef]
  57. Glass, N.L.; Donaldson, G.C. Development of Primer Sets Designed for Use with the PCR to Amplify Conserved Genes from Filamentous Ascomycetes. Appl. Environ. Microbiol. 1995, 61, 1323–1330. [Google Scholar] [CrossRef]
  58. Hong, S.-B.; Go, S.-J.; Shin, H.-D.; Frisvad, J.C.; Samson, R.A. Polyphasic Taxonomy of Aspergillus fumigatus and Related Species. Mycologia 2005, 97, 1316–1329. [Google Scholar] [CrossRef]
  59. Choukri, F.; Botterel, F.; Sitterlé, E.; Bassinet, L.; Foulet, F.; Guillot, J.; Costa, J.M.; Fauchet, N.; Dannaoui, E. Prospective Evaluation of Azole Resistance in Aspergillus fumigatus Clinical Isolates in France. Med. Mycol. 2015, 53, 593–596. [Google Scholar] [CrossRef]
  60. The European Committee on Antimicrobial Susceptibility Testing. Overview of Antifungal ECOFFs and Clinical Breakpoints for Yeasts, Moulds and Dermatophytes Using the EUCAST E.Def 7.3, E.Def 9.4 and E.Def 11.0 Procedures. Version 3. 2022. Available online: http://www.eucast.org (accessed on 1 September 2023).
  61. Saitou, N.; Nei, M. The Neighbor-Joining Method: A New Method for Reconstructing Phylogenetic Trees. Mol. Biol. Evol. 1987, 4, 406–425. [Google Scholar] [CrossRef]
  62. Felsenstein, J. Confidence Limits on Phylogenies: An Approach Using the Bootstrap. Evolution 1985, 39, 783–791. [Google Scholar] [CrossRef] [PubMed]
  63. Tamura, K.; Nei, M.; Kumar, S. Prospects for Inferring Very Large Phylogenies by Using the Neighbor-Joining Method. Proc. Natl. Acad. Sci. USA 2004, 101, 11030–11035. [Google Scholar] [CrossRef] [PubMed]
  64. Tamura, K.; Stecher, G.; Kumar, S. MEGA11: Molecular Evolutionary Genetics Analysis Version 11. Mol. Biol. Evol. 2021, 38, 3022–3027. [Google Scholar] [CrossRef] [PubMed]
  65. Jorgensen, T.R. Identification and Toxigenic Potential of the Industrially Important Fungi, Aspergillus oryzae and Aspergillus sojae. J. Food Prot. 2007, 70, 2916–2934. [Google Scholar] [CrossRef]
  66. Tam, E.W.T.; Chen, J.H.K.; Lau, E.C.L.; Ngan, A.H.Y.; Fung, K.S.C.; Lee, K.-C.; Lam, C.-W.; Yuen, K.-Y.; Lau, S.K.P.; Woo, P.C.Y. Misidentification of Aspergillus nomius and Aspergillus tamarii as Aspergillus flavus: Characterization by Internal Transcribed Spacer, β-Tubulin, and Calmodulin Gene Sequencing, Metabolic Fingerprinting, and Matrix-Assisted Laser Desorption Ionization-Time of Flight Mass Spectrometry. J. Clin. Microbiol. 2014, 52, 1153–1160. [Google Scholar] [CrossRef]
  67. Caira, M.; Posteraro, B.; Sanguinetti, M.; de Carolis, E.; Leone, G.; Pagano, L. First Case of Breakthrough Pneumonia Due to Aspergillus nomius in a Patient with Acute Myeloid Leukemia. Med. Mycol. J. 2012, 50, 746–750. [Google Scholar] [CrossRef]
  68. Perez, L.; Messina, F.; Negroni, R.; Arechavala, A.; Bustamante, J.; Oleastro, M.; Migaud, M.; Casanova, J.-L.; Puel, A.; Santiso, G. Inherited CARD9 Deficiency in a Patient with Both Exophiala spinifera and Aspergillus nomius Severe Infections. J. Clin. Immunol. 2020, 40, 359–366. [Google Scholar] [CrossRef]
  69. Zotti, M.; Machetti, M.; Persi, A.; Barabino, G.; Parodi, A. Onychomycosis: First Case Due to Aspergillus nomius. Acta Derm. Venereol. 2011, 91, 591–592. [Google Scholar] [CrossRef]
  70. Manikandan, P.; Varga, J.; Kocsubé, S.; Samson, R.A.; Anita, R.; Revathi, R.; Dóczi, I.; Németh, T.M.; Narendran, V.; Vágvölgyi, C.; et al. Mycotic Keratitis Due to Aspergillus nomius. J. Clin. Microbiol. 2009, 47, 3382–3385. [Google Scholar] [CrossRef]
  71. Zhou, Y.B.; Li, D.M.; Houbraken, J.; Sun, T.T.; de Hoog, G.S. Fatal Rhinofacial Mycosis Due to Aspergillus nomiae: Case Report and Review of Published Literature. Front. Microbiol. 2020, 11, 595375. [Google Scholar] [CrossRef]
  72. Salah, H.; Lackner, M.; Houbraken, J.; Theelen, B.; Lass-Flörl, C.; Boekhout, T.; Almaslamani, M.; Taj-Aldeen, S.J. The Emergence of Rare Clinical Aspergillus Species in Qatar: Molecular Characterization and Antifungal Susceptibility Profiles. Front. Microbiol. 2019, 10, 1677. [Google Scholar] [CrossRef] [PubMed]
  73. Alshehri, B.; Palanisamy, M. Evaluation of Molecular Identification of Aspergillus Species Causing Fungal Keratitis. Saudi J. Biol. Sci. 2020, 27, 751–756. [Google Scholar] [CrossRef] [PubMed]
  74. Kimura, H.; Mitsuto, I.; Taguchi, R.; Anzawa, K.; Mochizuki, T. Primary Cutaneous Aspergillosis Caused by Aspergillus tamarii in a Premature Infant with Extremely Low Birthweight: A Case Report with Short Review. J. Dermatol. 2018, 45, 622–625. [Google Scholar] [CrossRef] [PubMed]
  75. Sharma, S.; Madhav Yenigalla, B.; Kumar Naidu, S.; Pidakala, P. Primary Cutaneous Aspergillosis Due to Aspergillus tamarii in an Immunocompetent Host. Br. Med. J. Case Rep. 2013, 2013, bcr2013010128. [Google Scholar] [CrossRef] [PubMed]
  76. Aries, P.; Hoffmann, C.; Schaal, J.-V.; Leclerc, T.; Donat, N.; Cirodde, A.; Masson, Y.; Renner, J.; Soler, C. Aspergillus tamarii: An Uncommon Burn Wound Infection. J. Clin. Pathol. 2018, 71, 379–380. [Google Scholar] [CrossRef] [PubMed]
  77. Gómez, O.M.; Freyle, C.G.; Torres, S.; Rúa, Á.L.; Tamayo, D.P.; McEwen, J.G.; Borges, C.L.; Hernández, O. Draft Genome Sequences of Clinical and Environmental Isolates of Aspergillus tamarii from Colombia. Microbiol. Resour. Announc. 2020, 9, e01514–e01519. [Google Scholar] [CrossRef]
  78. Kristensen, L.; Stenderup, J.; Otkjaer, A. Onychomycosis Due to Aspergillus tamarii in a 3-Year-Old Boy. Acta Derm. Venereol. 2005, 85, 261–262. [Google Scholar] [CrossRef]
  79. Ghosh, A.; Kaur, H.; Gupta, A.; Singh, S.; Rudramurthy, S.M.; Gupta, S.; Chakrabarti, A. Emerging Dematiaceous and Hyaline Fungi Causing Keratitis in a Tertiary Care Centre from North India. Cornea 2020, 39, 868–876. [Google Scholar] [CrossRef]
  80. Paludetti, G.; Rosignoli, M.; Ferri, E.; Cesari, M.R.; Morace, G.; Fantoni, M.; Galli, J. Invasive nasosinusal aspergillosis in an immunocompetent patient. Acta Otorhinolaryngol. Ital. 1992, 12, 581–591. [Google Scholar]
  81. Kamble, R.; Joshi, J.; Pendurkar, S. Paranasal Sinus Aspergillosis: A Case Report and Review of Literature. Int. J. Curr. Microbiol. App. Sci. 2015, 4, 314–322. [Google Scholar]
  82. Ozhak-Baysan, B.; Alastruey-Izquierdo, A.; Saba, R.; Ogunc, D.; Ongut, G.; Timuragaoglu, A.; Arslan, G.; Cuenca-Estrella, M.; Rodriguez-Tudela, J.L. Aspergillus alliaceus and Aspergillus flavus Co-Infection in an Acute Myeloid Leukemia Patient. Med. Mycol. 2010, 48, 995–999. [Google Scholar] [CrossRef] [PubMed]
  83. Balajee, S.A.; Lindsley, M.D.; Iqbal, N.; Ito, J.; Pappas, P.G.; Brandt, M.E. Nonsporulating Clinical Isolate Identified as Petromyces alliaceus (Anamorph Aspergillus alliaceus) by Morphological and Sequence-Based Methods. J. Clin. Microbiol. 2007, 45, 2701–2703. [Google Scholar] [CrossRef] [PubMed]
  84. Bayman, P.; Baker, J.L.; Doster, M.A.; Michailides, T.J.; Mahoney, N.E. Ochratoxin Production by the Aspergillus ochraceus Group and Aspergillus alliaceus. Appl. Environ. Microbiol. 2002, 68, 2326–2329. [Google Scholar] [CrossRef] [PubMed]
  85. Xu, Y.; Chen, M.; Zhu, J.; Gerrits van den Ende, B.; Chen, A.J.; Al-Hatmi, A.M.S.; Li, L.; Zhang, Q.; Xu, J.; Liao, W.; et al. Aspergillus Species in Lower Respiratory Tract of Hospitalized Patients from Shanghai, China: Species Diversity and Emerging Azole Resistance. Infect. Drug Resist. 2020, 13, 4663–4672. [Google Scholar] [CrossRef]
  86. Le Pape, P.; Ximenes, R.M.; Ariza, B.; Iriarte, J.; Alvarado, J.; Robert, E.; Sierra, C.; Montañez, A.; Álvarez-Moreno, C. First Case of Aspergillus caelatus Airway Colonization in a Chronic Obstructive Pulmonary Disease Patient. Int. J. Infect. Dis. 2019, 81, 85–90. [Google Scholar] [CrossRef]
  87. Karimizadeh Esfahani, M.; Eslampoor, A.; Dolatabadi, S.; Najafzadeh, M.J.; Houbraken, J. First Case of Fungal Keratitis Due to Aspergillus minisclerotigenes in Iran. Curr. Med. Mycol. 2019, 5, 45–48. [Google Scholar] [CrossRef]
  88. Gonçalves, S.S.; Stchigel, A.M.; Cano, J.F.; Godoy-Martinez, P.C.; Colombo, A.L.; Guarro, J. Aspergillus novoparasiticus: A New Clinical Species of the Section Flavi. Med. Mycol. 2012, 50, 152–160. [Google Scholar] [CrossRef]
  89. Arias, R.S.; Orner, V.A.; Martinez-Castillo, J.; Sobolev, V.S. Aspergillus Section Flavi, Need for a Robust Taxonomy. Microbiol. Resour. Announc. 2021, 10, e0078421. [Google Scholar] [CrossRef]
  90. Abbas, A.; Hussien, T.; Yli-Mattila, T. A Polyphasic Approach to Compare the Genomic Profiles of Aflatoxigenic and Non-Aflatoxigenic Isolates of Aspergillus Section Flavi. Toxins 2020, 12, 56. [Google Scholar] [CrossRef]
  91. Quéro, L.; Courault, P.; Cellière, B.; Lorber, S.; Jany, J.-L.; Puel, O.; Girard, V.; Vasseur, V.; Nodet, P.; Mounier, J. Application of MALDI-TOF MS to Species Complex Differentiation and Strain Typing of Food Related Fungi: Case Studies with Aspergillus Section Flavi Species and Penicillium roqueforti Isolates. Food Microbiol. 2020, 86, 103311. [Google Scholar] [CrossRef]
  92. Tuchtan, L.; Piercecchi-Marti, M.-D.; Dumon, H.; Métras, D.; Léonetti, G.; Bartoli, C. Medicolegal Implications of Nosocomial Infections: A Case Report of Aspergillus Contamination during Cardiac Surgery. J. Forensic Sci. 2017, 62, 815–818. [Google Scholar] [CrossRef] [PubMed]
  93. Sharma, C.; Kumar, R.; Kumar, N.; Masih, A.; Gupta, D.; Chowdhary, A. Investigation of Multiple Resistance Mechanisms in Voriconazole-Resistant Aspergillus flavus Clinical Isolates from a Chest Hospital Surveillance in Delhi, India. Antimicrob. Agents Chemother. 2018, 62, e01928-17. [Google Scholar] [CrossRef] [PubMed]
  94. Rivero-Menendez, O.; Soto-Debran, J.C.; Medina, N.; Lucio, J.; Mellado, E.; Alastruey-Izquierdo, A. Molecular Identification, Antifungal Susceptibility Testing, and Mechanisms of Azole Resistance in Aspergillus Species Received within a Surveillance Program on Antifungal Resistance in Spain. Antimicrob. Agents Chemother. 2019, 63, e00865-19. [Google Scholar] [CrossRef] [PubMed]
  95. Lucio, J.; Gonzalez-Jimenez, I.; Rivero-Menendez, O.; Alastruey-Izquierdo, A.; Pelaez, T.; Alcazar-Fuoli, L.; Mellado, E. Point Mutations in the 14-α Sterol Demethylase Cyp51A or Cyp51C Could Contribute to Azole Resistance in Aspergillus flavus. Genes. 2020, 11, 1217. [Google Scholar] [CrossRef]
  96. Ferraz, T.L.L.; Araújo, E.M.; Calixto, R.F.; Sampaio, M.L.M.; de Mello, L.R.B.; Torres, K.B.; de Aguiar Cordeiro, R.; Le Pape, P.; Gonçalves de Lima-Neto, R. Lethal Destructive Sinusopathy Due to Amphotericin B-Resistant Aspergillus flavus: A Case Report. Rev. Iberoam. Micol. 2022, 39, 21–24. [Google Scholar] [CrossRef]
  97. Dannaoui, E.; Espinel-Ingroff, A. Antifungal Susceptibly Testing by Concentration Gradient Strip Etest Method for Fungal Isolates: A Review. J. Fungi 2019, 5, 108. [Google Scholar] [CrossRef]
Microorganisms 11 02429 g001
Figure 1. Phylogenetic tree of A. flavus of concatenated partial β-tubulin and calmodulin sequences. (A) All isolates and reference sequences. (B) Only A. flavus ss with A. aflatoxiformans as outgroup. The evolutionary history was inferred using the Neighbor-joining method [61]. The optimal tree is shown. The percentage of replicate trees in which the associated taxa clustered together in the bootstrap test (1000 replicates) are shown next to the branches [62]. The tree is drawn to scale, with branch lengths in the same units as those of the evolutionary distances used to infer the phylogenetic tree. The evolutionary distances were computed using the Maximum Composite Likelihood method [63] and are in the units of the number of base substitutions per site. This analysis involved 175 nucleotide sequences. All ambiguous positions were removed for each sequence pair (pairwise deletion option). There was a total of 970 positions in the final dataset. Evolutionary analyses were conducted in MEGA11 [64].
Figure 1. Phylogenetic tree of A. flavus of concatenated partial β-tubulin and calmodulin sequences. (A) All isolates and reference sequences. (B) Only A. flavus ss with A. aflatoxiformans as outgroup. The evolutionary history was inferred using the Neighbor-joining method [61]. The optimal tree is shown. The percentage of replicate trees in which the associated taxa clustered together in the bootstrap test (1000 replicates) are shown next to the branches [62]. The tree is drawn to scale, with branch lengths in the same units as those of the evolutionary distances used to infer the phylogenetic tree. The evolutionary distances were computed using the Maximum Composite Likelihood method [63] and are in the units of the number of base substitutions per site. This analysis involved 175 nucleotide sequences. All ambiguous positions were removed for each sequence pair (pairwise deletion option). There was a total of 970 positions in the final dataset. Evolutionary analyses were conducted in MEGA11 [64].
Microorganisms 11 02429 g001
Table 1. MIC distribution of 6 antifungal drugs against 120 A. flavus ss isolates.
Table 1. MIC distribution of 6 antifungal drugs against 120 A. flavus ss isolates.
Antifungal DrugsNumber of Isolates for the Following MIC (mg/L)
0.0150.030.060.1250.250.51248
VRZ-----58537-2
ISA-----198118-2
ITZ---29642331--
PSZ-1152454188 --
AMB----123451311
CAS-208317------
VRZ: voriconazole; ISA: isavuconazole; ITZ: itraconazole; PSZ: posaconazole; AMB: amphotericin B; CAS: caspofungin. Resistant isolates (MIC > 1 mg/L for ITZ, MIC > 2 mg/L for ISA) and non-wild-type isolates (MIC was >4 mg/L for AMB, >2 mg/L for VRZ, and >0.5 mg/L for PSZ) are indicated in bold.
Table 2. Statistical indices of the distribution of MICs for 6 antifungal drugs against 120 A. flavus ss isolates.
Table 2. Statistical indices of the distribution of MICs for 6 antifungal drugs against 120 A. flavus ss isolates.
Indice (mg/L)Antifungal Drug (mg/L)
VRZISAITZPSZAMBCAS
Min0.50.50.1250.0310.250.03
Max882180.125
GMean0.771.030.250.221.910.06
MIC50110.250.2520.06
MIC90120.50.540.125
VRZ: voriconazole; ISA: isavuconazole; ITZ: itraconazole; PSZ: posaconazole; AMB: amphotericin B; CAS: caspofungin; Min: minimum; Max: maximum; GMean: geometric mean; MIC50: minimal inhibitory concentration that inhibits 50% of the isolates; MIC90: minimal inhibitory concentration that inhibits 90% of the isolates.
Table 3. MICs for the two cryptic species.
Table 3. MICs for the two cryptic species.
SpeciesMIC (mg/L)
VRZISAITZPSZAMBCAS
A. parasiticus0.50.50.250.12520.06
A. nomiae0.510.50.2540.03
MICs were determined by the EUCAST method. VRZ: voriconazole; ISA: isavuconazole; ITZ: itraconazole; PSZ: posaconazole; AMB: amphotericin B; CAS: caspofungin.
Table 4. Flavi section cryptic species in the literature.
Table 4. Flavi section cryptic species in the literature.
SpeciesLocalization of InfectionTreatmentOutcomeReference
LocalSystemic
A. alliaceusLungNoneVRZSurvived[46]
A. alliaceusLungNoneVRZDeath[82]
A. alliaceusLungNoneAMB + CAS, then ITZDeath[83]
A. caelatusLung (colonization)nonenoneNA[86]
A. minisclerotigenesSinusNANANA[45]
A. minisclerotigenesParanasalNANANA[45]
A. minisclerotigenesEyeAMB + VRZFCZCorneal transplant[87]
A. novoparasiticusLungNANANA[88]
A. novoparasiticusLungNANANA[88]
A. nomiaeLungnoneAMB + ITZDeath[66]
A. nomiaeLungnoneITZSurvived[66]
A. nomiaeCornealNTM, ECZ, ITZ, KTZnoneCorneal perforation, scleral extension[70]
A. nomiaeNailAmorolfineITZCured[69]
A. nomiaeSputumVRZnoneDeath[67]
A. nomiaeLungAMB nebulizedISA + AnidulafunginDeath[46]
A. nomiaeSkinnoneAMBDeath[71]
A. nomiaeLungnoneCAS + PSZ + bilobectomyCured[68]
A. nomiaeEyeNANA [73]
A. oryzea var. effususEyenonenoneTectonic KP, vitrectomy[6]
A. pseudonomiaeSinus tissuesurgery Cured[72]
A. pseudonomiaeEyeNA NA[73]
A.pseudonomiaeEye [7]
A. pseudotamariiEyeNTM; ITZITZImproved[11]
A. tamariiEyeNTM, ECZ (then CLT), ITZKTZGood response, no follow-up[10]
A. tamariiEyeNTM, ECZ (then CLT), ITZKTZHealed, no follow-up[10]
A. tamariiEyeNTM, ECZ, ITZ, AMBKTZEvisceration[10]
A. tamariiEyeNTM, ITZKTZHealed[10]
A. tamariiEyeNTM, ECZ, ITZKTZHealed[10]
A. tamariiEyeNTM, ECZ, ITZKTZNo response, no follow-up[10]
A. tamariiEyeNTM, ECZ, FCZKTZImproved, central nebular scar[9]
A. tamariiEyeVRZ, AMB, NTMAMB, VRZImproved, extensive corneal scar[8]
A. tamariiEyeVRZITZImproved, no surgery[6]
A. tamariiEyeVRZ after surgerynoneTectonic KP, vitrectomy[6]
A. tamariiEyeVRZ after surgerynoneTectonic KP, vitrectomy[6]
A. tamariiEyeVRZnoneTectonic KP, OKP, intraocular lens[6]
A. tamariiSkinCLTAMB ivResolving of cutaneous lesions[74]
A. tamariiSkinnoneITZComplete recovery[75]
A. tamariiNasosinusal ITZ and surgeryExcellent local results at a follow-up of one year[80]
A. tamariiSputum (colonization)nonenoneSurvived[66]
A. tamariiNailUrea cream, Terbinafine Cured[78]
A. tamariiCorneal NANANA[7]
A. tamariiEyeNTMITZVascularized corneal opacity[79]
A. tamariiTissue (RTA) AMB [72]
A. tamariiSkin AMBVRZ then AMBSurvived[76]
A. tamariiLeft foot biopsyNANANA[77]
KTZ: Ketoconazole; ECZ: Econazole; NTM: Natamycin; VRZ: Voriconazole; FCZ: Fluconazole; ITZ: Itraconazole; PSZ: Posaconazole; AMB: Amphotericin B; CLT: Clotrimazole; Ref: reference.
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Share and Cite

MDPI and ACS Style

Djenontin, E.; Costa, J.-M.; Mousavi, B.; Nguyen, L.D.N.; Guillot, J.; Delhaes, L.; Botterel, F.; Dannaoui, E. The Molecular Identification and Antifungal Susceptibility of Clinical Isolates of Aspergillus Section Flavi from Three French Hospitals. Microorganisms 2023, 11, 2429. https://doi.org/10.3390/microorganisms11102429

AMA Style

Djenontin E, Costa J-M, Mousavi B, Nguyen LDN, Guillot J, Delhaes L, Botterel F, Dannaoui E. The Molecular Identification and Antifungal Susceptibility of Clinical Isolates of Aspergillus Section Flavi from Three French Hospitals. Microorganisms. 2023; 11(10):2429. https://doi.org/10.3390/microorganisms11102429

Chicago/Turabian Style

Djenontin, Elie, Jean-Marc Costa, Bita Mousavi, Lin Do Ngoc Nguyen, Jacques Guillot, Laurence Delhaes, Françoise Botterel, and Eric Dannaoui. 2023. "The Molecular Identification and Antifungal Susceptibility of Clinical Isolates of Aspergillus Section Flavi from Three French Hospitals" Microorganisms 11, no. 10: 2429. https://doi.org/10.3390/microorganisms11102429

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop